TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by thr...

Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by...

NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investor...

Vertex is diversifying, moving beyond a therapeutic area it has thoroughly dominated. Regeneron has three important growth drivers and a pipeline that should produce more.

Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition. Grace...

Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage study.

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall St...

U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.

Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revis...

Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metri...

Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and ...